As lawsuits against Injectafer continued to move forward in the Eastern District of Pennsylvania, many plaintiffs claimed that the drug manufacturer failed to warn about the risks associated with the drug, particularly dangerous side effects like hypophosphatemia. In response, a motion was filed to combine two of the cases for a single trial to save judicial resources. However, the court decided to hold separate trials for the first two bellwether cases, meaning they would be tried individually to better understand how juries may respond to the evidence presented.
[fluentform id=”15″]
